Drug Trial Radar · NCT05212246
Basal Cell Carcinoma Chemoprevention Trial
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,630
Planned (sponsor's estimate)
Start
Oct 6, 2026
Primary completion
Oct 6, 2032
Study completion Oct 6, 2032
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Jan 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.
Conditions
- Basal Cell Carcinoma
Interventions
5% Imiquimod creamDrug
Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Placebo Vehicle Control CreamDrug
The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with a new Basal Cell Carcinoma (BCC) on the face at 1 yearTime frame: 1 year from the time of randomization
- Basal Cell Carcinoma (BCC) free time to a new BCC on the face over 3 yearsTime frame: 3 years from the time of randomization
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California · Recruiting
VA San Diego Healthcare System, San Diego, CA
San Diego, California · Recruiting
Bay Pines VA Healthcare System, Pay Pines, FL
Bay Pines, Florida · Recruiting
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota · Recruiting
Durham VA Medical Center, Durham, NC
Durham, North Carolina · Recruiting
Providence VA Medical Center, Providence, RI
Providence, Rhode Island · Not yet recruiting
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah · Recruiting
Clement J. Zablocki VA Medical Center, Milwaukee, WI
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.